Drug price talks provide an early test for Trump

The Biden administration within days is expected to select the next batch of drugs that will be subject to Medicare price negotiations — a process that this time could include Novo Nordisk's blockbusters Ozempic and Wegovy.

Why it matters: The political appeal of bringing down the price of the wildly popular drugs and other medicines for seniors could outweigh deep misgivings in Republican circles about one of Democrats' most significant health policy achievements.